TeamDrive
RUS

R&D Center of NovaMedica has received GMP-Certificate from the Ministry of Industry and Trade of the Russian Federation

26 December 2017

Moscow, December 26, 2017 – Russian pharmaceutical company NovaMedica, investment project of Rusnano, informed about receipt of conclusion of the Ministry of Industry and Trade of the Russian Federation over compliance of the facility of the R&D Center of NovaMedica Innotech (subsidiary of NovaMedica) with the Russian standards of the Good Manufacturing Practice (GMP). The certificate issued basing on the integrated audit of the MIT RF commission, proves that the processes of development, manufacturing and quality control at NovaMedica Innotech are organized in accordance with the high standards of quality and manufacturing of tablets, soft and hard gelatin capsules and pellets at its manufacturing facilities meet the Russian GMP requirements. 

«Now R&D Center will be able to provide partners with rather rare in the Russian pharmaceutical market set of services that includes development and manufacturing of complex drug products including with usage of exclusive for our market technologies such as hot extrusion, spheronization of granules, covering of pellets in a liquid bed. I am sure that positive conclusion from the experts regarding compliance of the manufacturing facility of NovaMedica Innotech with the GMP requirements will serve as an additional reason for our partners in making decision over selection of a CMO site for development and manufacturing in Russia”, noted Alexander Kuzin, CEO of NovaMedica.

Further plans of the R&D Center of NovaMedica include receipt of the international GMP certificate.

About NovaMedica

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects

NovaMedica became key partner of Pfizer in Russia in 2016. Within this partnership NovaMedica started construction of the pharmaceutical GMP manufacturing facility in the Kaluga region in May 2017. In December 2017 Interdepartmental Commission approved NovaMedica’s application for SPIC to create new pharmaceutical manufacturing facility in the Kaluga region.

In April 2017 NovaMedica opened the Technological Center with state-of-the-art technological capabilities which were previously unavailable in the Russian pharmaceutical industry. In Q4 2017 R&D Center of NovaMedica received manufacturing license and the Russian GMP certificate from the Ministry of Industry and Trade of the Russian Federation.

NovaMedica possesses a well-developed infrastructure for promotion and sale of pharmaceutical products. Currently company is promoting a portfolio of 25 ophthalmological and gastroenterological products in the Russian market.  

More information here www.novamedica.com, follow us on Facebook and LinkedIn.


Previous publication Next publication

Media Center

  • 23 October 2018

    Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients

    Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment.

  • 23 October 2018

    Russian cancer drug based on smallpox vaccine undergoes preclinical studies

    Siberian scientists have brought to the final stage of preclinical testing the only Russian therapeutic cancer drug. This part of the study is expected to be completed by the end of 2019, according to Sergei Netesov, Chairman of the Board of the Association for the Development of the Innovative Territorial Cluster of the Novosibirsk Region in the Sphere of Biopharmaceutical Technologies (‘Biopharm’).

  • 22 October 2018

    Pfizer preps for BMS showdown with Bavencio kidney cancer combo data

    Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-gen rival Bristol-Myers Squibb—with its latest data. Sunday at the European Society for Medical Oncology annual meeting, the New York drugmaker and partner Merck KGaA said their immuno-oncology agent Bavencio, in tandem with Pfizer’s Inlyta, had staved off cancer progression in previously untreated patients by a median 13.8 months, compared with 8.4 months for standard-of-care Sutent, another Pfizer drug.

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

Read more